<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621905</url>
  </required_header>
  <id_info>
    <org_study_id>MPG010</org_study_id>
    <nct_id>NCT02621905</nct_id>
  </id_info>
  <brief_title>Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc速 50 mg With Sporanox速 100 mg</brief_title>
  <official_title>Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc速 (Mayne) Regardless of Food With Sporanox速 (Janssen) Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayne Pharma International Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayne Pharma International Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of Sporanox and Lozanoc has not been compared in patients requiring&#xD;
      anti-fungal prophylaxis or therapy. The present study is designed to compare the&#xD;
      pharmacokinetics of Sporanox and Lozanoc in patients requiring primary prophylaxis. The&#xD;
      3-week exposure to each formulation is designed to allow for all participants to reach&#xD;
      steady-state for each drug, as the time to steady-state can vary.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After confirmation of eligibility, participants will be randomly assigned 1:1 to commence&#xD;
      therapy with either 100mg mane and 100mg nocte for 21 days or Sporanox 200mg mane and 200mg&#xD;
      nocte with food for 21 days. If a subject enters the study already receiving itraconazole&#xD;
      prophylaxis at a dose of itraconazole higher than 100 mg twice a day, the subject will then&#xD;
      be dosed on study at the pre-study dosage; that is, the subject will take the same number of&#xD;
      capsules per day on study as the subject was taking prior to enrolment in the study.&#xD;
&#xD;
      The following information will be collected at baseline; whether the participant is taking&#xD;
      itraconazole prophylaxis and at what dose; whether the participant is taking gastric&#xD;
      suppression therapy. Patients who are not taking food or who are taking gastric acid&#xD;
      suppression therapy (antacids, an H2 antagonist or a proton pump inhibitor) can take Sporanox&#xD;
      with cola or orange juice to maximise absorption as recommended in the Sporanox product label&#xD;
      (not required for Lozanoc formulation).&#xD;
&#xD;
      At Day 22, participants assigned to&#xD;
&#xD;
        -  Lozanoc and who have completed 21 days of Lozanoc prophylaxis will cross over to the&#xD;
           same number of Sporanox capsules with food for a further 21 days&#xD;
&#xD;
        -  Sporanox and who have completed 21 days of Sporanox prophylaxis will cross over to the&#xD;
           same number of Lozanoc capsules for a further 21 days.&#xD;
&#xD;
      The dose of either drug may be dose-reduced or ceased for toxicity at the discretion of the&#xD;
      investigator.&#xD;
&#xD;
      During the course of the treatment periods participants will undergo the following&#xD;
      assessments:&#xD;
&#xD;
        -  Concurrent medication(s)&#xD;
&#xD;
        -  Clinical adverse events&#xD;
&#xD;
        -  Measurement of vital signs (weight, blood pressure, temperature)&#xD;
&#xD;
        -  Targeted physical examination&#xD;
&#xD;
        -  Documentation of any evidence of systemic fungal infection&#xD;
&#xD;
        -  Medication and meal diaries&#xD;
&#xD;
        -  12-lead electrocardiogram (ECG)&#xD;
&#xD;
        -  Laboratory safety assessments: Renal function and electrolytes (urea, creatinine,&#xD;
           estimated glomerular filtration rate [eGFR], sodium, potassium, chloride, bicarbonate),&#xD;
           Liver function tests (bilirubin, albumin, total protein, alanine aminotransferase [ALT],&#xD;
           aspartate aminotransferase [AST])&#xD;
&#xD;
        -  Pharmacokinetic testing: Trough (pre-morning dose; 0 hr) sample will be collected at&#xD;
           Baseline (Day 1), and at Days 8, 15, 22, 29, 36 and 43. Post-dose samples will also be&#xD;
           collected 2, 3.5 and 6 hours after the morning dose on Day 22 and Day 43&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative steady-state bioavailability</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Sporanox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lozanoc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sporanox</intervention_name>
    <description>At least 2 capsules twice a day for 3 weeks</description>
    <arm_group_label>Sporanox</arm_group_label>
    <other_name>itraconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lozanoc</intervention_name>
    <description>At least 2 capsules twice a day for 3 weeks</description>
    <arm_group_label>Lozanoc</arm_group_label>
    <other_name>itraconazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written, informed consent&#xD;
&#xD;
          -  Age of at least 18 years&#xD;
&#xD;
          -  No clinical evidence of active systemic fungal infection&#xD;
&#xD;
          -  Physician-recommended primary prophylaxis against systemic fungal infections with&#xD;
             itraconazole in patients who have had or about to have: a heart, lung or bone marrow&#xD;
             transplant, combination chemotherapy for cancer; aspergilloma, chronic pulmonary&#xD;
             aspergillus bronchitis, or allergic bronchopulmonary aspergillosis&#xD;
&#xD;
          -  Patients may be receiving itraconazole prophylaxis prior to entry into the study&#xD;
&#xD;
          -  Body mass index between 15.0 and 35.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, planning pregnancy or breastfeeding&#xD;
&#xD;
          -  Congestive cardiac failure or other causes of ventricular dysfunction that may&#xD;
             outweigh the benefit of itraconazole&#xD;
&#xD;
          -  Hypersensitivity to either study drug or to any of their excipients&#xD;
&#xD;
          -  Coadministration of the following drugs:&#xD;
&#xD;
               -  CYP3A4 metabolised substrates that can prolong the QT-interval e.g., sertindole,&#xD;
                  terfenadine&#xD;
&#xD;
               -  CYP3A4 metabolised HMG-CoA reductase inhibitors e.g. simvastatin, lovastatin&#xD;
&#xD;
               -  Potent CYP3A4 inhibitors e.g. dronedarone&#xD;
&#xD;
               -  Triazolam, alprazolam and oral midazolam&#xD;
&#xD;
               -  Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and&#xD;
                  ergotamine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Marriott</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's Hospital, Sydney</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <keyword>Steady-State</keyword>
  <keyword>Bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual patient data will not be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

